Published in Virology on May 10, 2000
Varicella-zoster virus infection of human dorsal root ganglia in vivo. Proc Natl Acad Sci U S A (2005) 1.89
Tropism of varicella-zoster virus for human tonsillar CD4(+) T lymphocytes that express activation, memory, and skin homing markers. J Virol (2002) 1.53
Myelin-associated glycoprotein mediates membrane fusion and entry of neurotropic herpesviruses. Proc Natl Acad Sci U S A (2009) 1.37
Microarray analysis of host cell gene transcription in response to varicella-zoster virus infection of human T cells and fibroblasts in vitro and SCIDhu skin xenografts in vivo. J Virol (2003) 1.33
Varicella-zoster virus infection of human dendritic cells and transmission to T cells: implications for virus dissemination in the host. J Virol (2001) 1.15
Simian varicella virus pathogenesis. Curr Top Microbiol Immunol (2010) 1.08
The varicella-zoster virus genome. Curr Top Microbiol Immunol (2010) 1.02
A systematic analysis of host factors reveals a Med23-interferon-λ regulatory axis against herpes simplex virus type 1 replication. PLoS Pathog (2013) 0.98
The varicella-zoster virus ORF47 kinase interferes with host innate immune response by inhibiting the activation of IRF3. PLoS One (2011) 0.89
Rodent models of varicella-zoster virus neurotropism. Curr Top Microbiol Immunol (2010) 0.84
Varicella-zoster virus modulates NF-kappaB recruitment on selected cellular promoters. J Virol (2007) 0.82
Fluorescent Protein Approaches in Alpha Herpesvirus Research. Viruses (2015) 0.82
Sialic Acids on Varicella-Zoster Virus Glycoprotein B Are Required for Cell-Cell Fusion. J Biol Chem (2015) 0.79
Three distinct antigens associated with human T-lymphocyte-mediated cytolysis: LFA-1, LFA-2, and LFA-3. Proc Natl Acad Sci U S A (1982) 7.16
Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature (1995) 6.85
LIGHT, a new member of the TNF superfamily, and lymphotoxin alpha are ligands for herpesvirus entry mediator. Immunity (1998) 4.23
Identification of women at unsuspected risk of primary infection with herpes simplex virus type 2 during pregnancy. N Engl J Med (1992) 3.91
A controlled trial of acyclovir for chickenpox in normal children. N Engl J Med (1991) 3.78
Prevention of transfusion-acquired cytomegalovirus infections in newborn infants. J Pediatr (1981) 3.42
Outbreak of ceftazidime resistance due to a novel extended-spectrum beta-lactamase in isolates from cancer patients. Antimicrob Agents Chemother (1992) 3.31
Natural history of neonatal herpes simplex virus infections in the acyclovir era. Pediatrics (2001) 2.91
Tropism of varicella-zoster virus for human CD4+ and CD8+ T lymphocytes and epidermal cells in SCID-hu mice. J Virol (1995) 2.87
The varicella-zoster virus immediate-early protein IE62 is a major component of virus particles. J Virol (1992) 2.80
Lymphotoxin beta, a novel member of the TNF family that forms a heteromeric complex with lymphotoxin on the cell surface. Cell (1993) 2.74
A lymphotoxin-beta-specific receptor. Science (1994) 2.73
Intrauterine infection with varicella-zoster virus after maternal varicella. N Engl J Med (1986) 2.63
Attenuation of the vaccine Oka strain of varicella-zoster virus and role of glycoprotein C in alphaherpesvirus virulence demonstrated in the SCID-hu mouse. J Virol (1998) 2.48
Varicella vaccine in pregnancy. BMJ (1996) 2.38
Rapid colorimetric assay for cell viability: application to the quantitation of cytotoxic and growth inhibitory lymphokines. J Immunol Methods (1984) 2.38
Mutational analysis of the role of glycoprotein I in varicella-zoster virus replication and its effects on glycoprotein E conformation and trafficking. J Virol (1997) 2.34
Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections. Pediatrics (2001) 2.30
TRAF5, an activator of NF-kappaB and putative signal transducer for the lymphotoxin-beta receptor. J Biol Chem (1996) 2.23
The ORF47 and ORF66 putative protein kinases of varicella-zoster virus determine tropism for human T cells and skin in the SCID-hu mouse. Proc Natl Acad Sci U S A (1998) 2.22
White matter asymmetry in the human brain: a diffusion tensor MRI study. Cereb Cortex (2004) 2.19
Reliability of a history of previous varicella infection in adults. JAMA (1997) 2.13
Characterization of a novel differentiation antigen complex recognize by a monoclonal antibody (A-1A5): unique activation-specific molecular forms on stimulated T cells. J Immunol (1983) 2.13
In vivo and in vitro analysis of transcriptional activation mediated by the human cytomegalovirus major immediate-early proteins. Mol Cell Biol (1993) 2.11
Motor cortex plasticity during constraint-induced movement therapy in stroke patients. Neurosci Lett (1998) 2.09
Role of the TRAF binding site and NF-kappaB activation in Epstein-Barr virus latent membrane protein 1-induced cell gene expression. J Virol (1998) 2.02
Low risk of herpes simplex virus infections in neonates exposed to the virus at the time of vaginal delivery to mothers with recurrent genital herpes simplex virus infections. N Engl J Med (1987) 1.99
Varicella-zoster virus gE escape mutant VZV-MSP exhibits an accelerated cell-to-cell spread phenotype in both infected cell cultures and SCID-hu mice. Virology (2000) 1.99
DeltaF508 CFTR protein expression in tissues from patients with cystic fibrosis. J Clin Invest (1999) 1.97
Failure of antepartum maternal cultures to predict the infant's risk of exposure to herpes simplex virus at delivery. N Engl J Med (1986) 1.94
Immune responses to measles and mumps vaccination of infants at 6, 9, and 12 months. J Infect Dis (2001) 1.90
The lymphotoxin-beta receptor is necessary and sufficient for LIGHT-mediated apoptosis of tumor cells. J Biol Chem (2000) 1.84
Hepatitis C virus core protein interacts with the cytoplasmic tail of lymphotoxin-beta receptor. J Virol (1997) 1.84
Deficiency of the humoral immune response to measles vaccine in infants immunized at age 6 months. JAMA (1998) 1.83
Frequencies of memory T cells specific for varicella-zoster virus, herpes simplex virus, and cytomegalovirus by intracellular detection of cytokine expression. J Infect Dis (2000) 1.81
Keratin-dependent, epithelial resistance to tumor necrosis factor-induced apoptosis. J Cell Biol (2000) 1.80
A metalloprotease inhibitor blocks shedding of the 80-kD TNF receptor and TNF processing in T lymphocytes. J Exp Med (1995) 1.76
Lymphotoxin-beta receptor signaling complex: role of tumor necrosis factor receptor-associated factor 3 recruitment in cell death and activation of nuclear factor kappaB. Proc Natl Acad Sci U S A (1997) 1.76
Targeted disruption of Traf5 gene causes defects in CD40- and CD27-mediated lymphocyte activation. Proc Natl Acad Sci U S A (1999) 1.76
Expression of alpha(4)beta(7) integrin defines a distinct pathway of lymphoid progenitors committed to T cells, fetal intestinal lymphotoxin producer, NK, and dendritic cells. J Immunol (2001) 1.73
Early immune response in healthy and immunocompromised subjects with primary varicella-zoster virus infection. J Infect Dis (1986) 1.72
Cutting edge: a novel viral TNF receptor superfamily member in virulent strains of human cytomegalovirus. J Immunol (1999) 1.68
Use of routine viral cultures at delivery to identify neonates exposed to herpes simplex virus. N Engl J Med (1988) 1.67
Application of the polymerase chain reaction to the diagnosis and management of neonatal herpes simplex virus disease. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. J Infect Dis (1996) 1.66
Constitutive expression of LIGHT on T cells leads to lymphocyte activation, inflammation, and tissue destruction. J Immunol (2001) 1.65
Detection of type-specific antibody to herpes simplex virus type 1 by radioimmunoassay with herpes simplex virus type 1 glycoprotein C purified with monoclonal antibody. Infect Immun (1983) 1.65
Investigation of varicella-zoster virus infection of lymphocytes by in situ hybridization. J Virol (1989) 1.64
CD27, a member of the tumor necrosis factor receptor superfamily, activates NF-kappaB and stress-activated protein kinase/c-Jun N-terminal kinase via TRAF2, TRAF5, and NF-kappaB-inducing kinase. J Biol Chem (1998) 1.64
A diverse family of proteins containing tumor necrosis factor receptor-associated factor domains. J Biol Chem (2001) 1.57
Essential role played by the C-terminal domain of glycoprotein I in envelopment of varicella-zoster virus in the trans-Golgi network: interactions of glycoproteins with tegument. J Virol (2001) 1.55
Mutational analysis of the repeated open reading frames, ORFs 63 and 70 and ORFs 64 and 69, of varicella-zoster virus. J Virol (2001) 1.53
Cell-mediated immunity of cytomegalovirus infection in normal subjects and cardiac transplant patients. J Infect Dis (1978) 1.51
Cellular and humoral immunity in the pathogenesis of recurrent herpes viral infections in patients with lymphoma. J Clin Invest (1980) 1.48
Acute renal failure following cocaine abuse. Nephron (1989) 1.46
The management of pregnancies complicated by genital infections with herpes simplex virus. Clin Infect Dis (1992) 1.45
Human cytomegalovirus UL144 open reading frame: sequence hypervariability in low-passage clinical isolates. J Virol (1999) 1.45
Fas and activation-induced Fas ligand mediate apoptosis of T cell hybridomas: inhibition of Fas ligand expression by retinoic acid and glucocorticoids. J Exp Med (1995) 1.45
Investigation of varicella-zoster virus infection by polymerase chain reaction in the immunocompetent host with acute varicella. J Infect Dis (1991) 1.43
The adenovirus E3-10.4K/14.5K complex mediates loss of cell surface Fas (CD95) and resistance to Fas-induced apoptosis. J Virol (1997) 1.43
Three adenovirus E3 proteins cooperate to evade apoptosis by tumor necrosis factor-related apoptosis-inducing ligand receptor-1 and -2. J Biol Chem (2000) 1.42
Spatial variability of fallout-90Sr in soil and vegetation of an alpine pasture. J Environ Radioact (2003) 1.41
Immunoglobulins M and G to varicella-zoster virus measured by solid-phase radioimmunoassay: antibody responses to varicella and herpes zoster infections. J Clin Microbiol (1980) 1.41
Mouse lymphotoxin-beta receptor. Molecular genetics, ligand binding, and expression. J Immunol (1995) 1.41
Selective impairment of lymphocyte reactivity to varicella-zoster virus antigen among untreated patients with lymphoma. J Infect Dis (1978) 1.40
Human lymphocyte function associated antigen-1 (LFA-1): identification of multiple antigenic epitopes and their relationship to CTL-mediated cytotoxicity. J Immunol (1983) 1.39
Lymphotoxins and cytomegalovirus cooperatively induce interferon-beta, establishing host-virus détente. Immunity (2001) 1.37
Effects of constraint-induced movement therapy on patients with chronic motor deficits after stroke: a replication. Stroke (1999) 1.36
Varicella-zoster virus retains major histocompatibility complex class I proteins in the Golgi compartment of infected cells. J Virol (2001) 1.36
Modulation of major histocompatibility class II protein expression by varicella-zoster virus. J Virol (2000) 1.30
Active site modulation in the N-acetylneuraminate lyase sub-family as revealed by the structure of the inhibitor-complexed Haemophilus influenzae enzyme. J Mol Biol (2000) 1.29
Type-specific antibodies to herpes simplex virus type 2 (HSV-2) glycoprotein G in pregnant women, infants exposed to maternal HSV-2 infection at delivery, and infants with neonatal herpes. J Infect Dis (1988) 1.29
IL-12, IFN-gamma, and T cell proliferation to measles in immunized infants. J Immunol (1999) 1.28
Subclinical varicella-zoster virus viremia, herpes zoster, and T lymphocyte immunity to varicella-zoster viral antigens after bone marrow transplantation. J Infect Dis (1992) 1.26
Genomic characterization of LIGHT reveals linkage to an immune response locus on chromosome 19p13.3 and distinct isoforms generated by alternate splicing or proteolysis. J Immunol (2001) 1.24
Physicochemical characterization of fluid phase (SC5b-9) and membrane derived (MC5b-9) attack complexes of human complement purified by immunoadsorbent affinity chromatography or selective detergent extraction. Mol Immunol (1981) 1.22
Adenovirus E3 14.7K protein functions in the absence of other adenovirus proteins to protect transfected cells from tumor necrosis factor cytolysis. J Virol (1991) 1.22
Lasting influence of repetitive transcranial magnetic stimulation on intracortical excitability in human subjects. Neurosci Lett (2000) 1.19
A rat anti-mouse kappa chain specific monoclonal antibody, 187.1.10: purification, immunochemical properties and its utility as a general second-antibody reagent. J Immunol Methods (1984) 1.18
Fusarium brain abscess. Case report. J Neurosurg (1983) 1.17
Use of polymerase chain reaction for successful identification of asymptomatic genital infection with herpes simplex virus in pregnant women at delivery. J Infect Dis (1990) 1.17
Immunologic evidence of reinfection with varicella-zoster virus. J Infect Dis (1983) 1.16
T lymphocyte cytotoxicity with natural varicella-zoster virus infection and after immunization with live attenuated varicella vaccine. J Immunol (1989) 1.15
Immunity to varicella-zoster viral glycoproteins, gp I (gp 90/58) and gp III (gp 118), and to a nonglycosylated protein, p 170. J Immunol (1986) 1.15
Expression of the lymphotoxin beta receptor on follicular stromal cells in human lymphoid tissues. Cell Death Differ (1998) 1.13
Relationship of antibody to outcome in neonatal herpes simplex virus infections. Infect Immun (1980) 1.12
The health data base of a nationwide company - its use in epidemiological studies. J Occup Med (1982) 1.11
Hepatitis C virus core protein: possible roles in viral pathogenesis. Curr Top Microbiol Immunol (2000) 1.11
Lymphotoxin is expressed as a heteromeric complex with a distinct 33-kDa glycoprotein on the surface of an activated human T cell hybridoma. J Biol Chem (1992) 1.10
The three HveA receptor ligands, gD, LT-alpha and LIGHT bind to distinct sites on HveA. Mol Immunol (2000) 1.10
Discrete signaling regions in the lymphotoxin-beta receptor for tumor necrosis factor receptor-associated factor binding, subcellular localization, and activation of cell death and NF-kappaB pathways. J Biol Chem (2000) 1.09
Neonatal antibody-dependent cellular cytotoxic antibody levels are associated with the clinical presentation of neonatal herpes simplex virus infection. J Infect Dis (1989) 1.08
Reasons for the absence of a history of recurrent genital infections in mothers of neonates infected with herpes simplex virus. Pediatrics (1984) 1.08
Human leukocyte interferon in the treatment of varicella in children with cancer: a preliminary controlled trial. Antimicrob Agents Chemother (1978) 1.08
Double-negative (CD4- CD8-) T cells with an alpha/beta T cell receptor. Non-MHC-restricted cytolytic activity and lymphokine production. J Immunol (1990) 1.08
Dominant negative mutants of TRAF3 reveal an important role for the coiled coil domains in cell death signaling by the lymphotoxin-beta receptor. J Biol Chem (1997) 1.07
Effect of leukocyte interferon on urinary excretion of cytomegalovirus by infants. J Infect Dis (1976) 1.06
Humoral and cell-mediated immunity in neonates with herpes simplex virus infection. J Infect Dis (1987) 1.06
Characterization of Varicella-Zoster virus glycoprotein K (open reading frame 5) and its role in virus growth. J Virol (1999) 1.06